- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06507930
COMPASSION-studien
COMPASSION-studien: Applying Telehealth for å innovere og styrke forbindelser for pasienter med metastatisk brystkreft som mottar hospice
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.
Study procedures include giving verbal consent to participate and a one-time survey delivered by email or phone call.
About 200 people, which includes 50 participants, 50 caregivers, 50 hospice nurses, and about 50 oncology providers, are expected to participate in this research study.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Claire Smith, MD
- Telefonnummer: 617-632-3800
- E-post: claire_smith@dfci.harvard.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Ta kontakt med:
- Claire Smith, MD
- Telefonnummer: 617-632-3800
- E-post: claire_smith@dfci.harvard.edu
-
Hovedetterforsker:
- Claire Smith, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient of any gender with unresectable locally advanced or metastatic breast cancer
- Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice </= 1 week before enrollment
- Ability to conduct video or phone check-ins, even if assistance required.
- Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
- Hospice setting is within Massachusetts
- Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
- Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment
Exclusion Criteria:
- Unable to provide verbal consent
- Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
- Hospice setting outside of Massachusetts
- Individuals who are under the age of 18, as this is not a project focused on pediatric patients.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Usual Care Cohort
25 participants will complete study procedures as follows:
|
|
|
Eksperimentell: Compassion Cohort
25 participants will complete study procedures as follows:
|
Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participant Intervention Completion
Tidsramme: Up to 4 weeks
|
Feasibility of the telehealth intervention is defined as greater than or equal to 80% of enrolled participants (18 out of 25) completing greater than or equal to 66% of the planned telehealth check-ins while the participant remains alive. |
Up to 4 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Claire Smith, MD, Dana-Farber Cancer Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 24-142
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Data can be shared no earlier than 1 year following the date of publication
Tilgangskriterier for IPD-deling
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .